Pharmacological characterization of histamine receptors in the human temporal artery.
1. The subtypes of histamine-receptors which mediate dilatation of small human temporal arteries have been characterized in vitro using 'selective' agonists and antagonists. 2. Dilatory responses were studied after preconstriction with prostaglandin F2 alpha since contraction was not seen at histamine concentrations up to 10(-4) M. Histamine caused a concentration-related relaxation of cerebral vessels with an IC50 value of 2.8 +/- 0.6 X 10(-7) M. 3. Cimetidine caused a parallel shift to the right of the histamine concentration-response curve whereas mepyramine was without observable effect. This suggests the presence of histamine H2-receptors only. However, combined treatment with mepyramine and cimetidine caused a more marked displacement of the concentration-response curve to the right. Schild analysis indicated that in situations of near complete blockade of the histamine H1-receptor subtypes, simple competitive antagonism at H2-receptors can be revealed with a pA2 value of 6.58 for cimetidine. The apparent pA2 value for mepyramine was 8.58. 4. The 'selective' H1-receptor agonists pyridylethylamine, 2-methylhistamine and thiazolylethylamine, and the H2-receptor agonists dimaprit, impromidine and 4-methylhistamine all mimicked the histamine response, but all except impromidine were less potent than histamine. The order of potency was impromidine greater than thiazolylamine greater than 4-Me-histamine greater than 2-Me-histamine greater than dimaprit greater than pyridylethylamine greater than tele-Me-histamine. 5. These results indicate that the histamine-induced dilatation in small human temporal arteries is mediated by both H1- and H2-receptors and that the latter subtype of histamine receptors predominates.
Ottosson
A
A
Department of Forensic Medicine, University of Lund, Sweden.
Jansen
I
I
Edvinsson
L
L
D000328:Adult; D002927:Cimetidine / Q000494:pharmacology; D015237:Dinoprost / Q000494:pharmacology; D005260:Female; D006632:Histamine / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D017446:Impromidine; D066298:In Vitro Techniques; D008297:Male; D008761:Methylhistamines / Q000494:pharmacology; D008875:Middle Aged; D011725:Pyridines / Q000494:pharmacology; D011738:Pyrilamine / Q000494:pharmacology; D011968:Receptors, Histamine / Q000032:analysis / Q000187:drug effects* / Q000502:physiology; D013699:Temporal Arteries / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D013844:Thiazoles / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
D007093:Imidazoles; D008761:Methylhistamines; D011725:Pyridines; D011968:Receptors, Histamine; D013844:Thiazoles; C029345:2-(2-aminoethyl)thiazole; D002927:Cimetidine; D006632:Histamine; D017446:Impromidine; C006183:2-(2-aminoethyl)pyridine; D015237:Dinoprost; D011738:Pyrilamine